- Follow Us
CDI Labs Services for
Patient Response and Adverse Reaction Prediction
Integrating autoantibody data with other clinical and molecular markers can enhance risk prediction models and facilitate personalized treatment.
REQUEST INFOHuProt to Improve Accuracy of Stratification
Predict both treatment response and immune-related adverse events
Autoantibodies can play a role in predicting patient response to treatment. Combining multiple autoantibodies into biomarker panels or signatures can improve the accuracy of stratification and predict both treatment response and immune-related adverse events (irAEs). Integrating autoantibody data with other clinical and molecular markers can enhance risk prediction models and facilitate personalized treatment approaches.
In the featured publication below, HuProt™ microarray was used to identify autoantibody signatures that have the potential to predict both disease recurrence and immune-related adverse events in melanoma patients treated with checkpoint inhibitor adjuvant immunotherapy.
Featured Publication
Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
Purpose
Adjuvant immunotherapy produces durable benefit for patients with resected melanoma, but many develop recurrence and/or immune-related adverse events (irAE). We investigated whether baseline serum autoantibody (autoAb) signatures predicted recurrence and severe toxicity in patients treated with adjuvant nivolumab, ipilimumab, or ipilimumab plus nivolumab.
VIEW PAPERCDI Labs Advantages
The most comprehensive protein collections available allow for rapid proteome wide antibody repertoire analysis and target identification studies.
HuProt™ Proteome Microarrays provide high quality, reproducible results with a protein purification process that only selects properly folded proteins.
GMP/GLP compliant workflows and highly trained technicians ensure the highest quality results. Compliant data management processes ensure data integrity and security.
Cutting-edge synthetic biology platforms and an innovative team with deep proteomics bench expertise make CDI Labs an ideal CRO partner for even your most challenging projects.HuProt Sample Requirements
Human serum or plasma
One 20 μL per sample
Antibody isolates
10 μg per sample (concentration 0.1 mg/mL)
Human cerebrospinal fluid (CSF)
Minimum 1.5 mL per sample
Protein / peptide / small molecule
10 μg per sample (concentration 0.1 mg/mL)
RNA
1 mL per sample (concentration 2 μM)